Orbimed Advisors LLC and Orbimed Capital Gp IX LLC Buys $20M of Windward BIO Group Ag (WWB) — SEC Form 4, Nov 18, 2026

Open-Market Net Purchase · SEC Form 4
+$20,000,007

Equity position changed by +1234.5%

Reporting Owners
Director 10% Owner
Director 10% Owner
TXN 2026-11-16 · FILED 2026-11-18
Equity Position 7.1M sh 531,864 → 7,097,715
Equity Change +1234.5% shares held after vs before
Insider Cluster 4 buying within 30 days — view cluster
Filing Lag 2 business days within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Filing Date
2026-11-18
Report Date
2026-11-18
Accession No.
0000947871-26-001038
Accepted At
2026-11-18 22:08 UTC
Reporting Owners
Name Relationship
Orbimed Advisors LLC CIK 0001055951
Director 10% Owner
Orbimed Capital Gp IX LLC CIK 0001920574
Director 10% Owner
Orbimed Advisors LLC at Windward BIO Group Ag Full insider history
Bought (12 mo) $20,000,007
Sold (12 mo) —
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Common SharesF1F2F3 2026-11-16 P - Purchase 1,176,471 A $17.00 +$20,000,007 1,708,103 Indirect See footnotes
Common SharesF4F2F3 2026-11-16 C - Conversion 3,561,936 A — 5,270,039 Indirect See footnotes
Common SharesF4F2F3 2026-11-16 C - Conversion 1,611,008 A — 6,881,047 Indirect See footnotes
Common SharesF5F2F3 2026-11-16 M - Exercise 216,668 A $0.02 +$4,333 7,097,715 Indirect See footnotes
Common SharesF6F2F3 2026-11-16 F - Tax Payment 232 D $17.00 -$3,944 7,097,483 Indirect See footnotes
Derivative Securities Transactions
Title Strike Date Type Shares Price Expiration Underlying Ownership
Series A Preferred SharesF4F4F4F2F3 2026-11-16 C - Conversion 3,561,936 D $0.00 3,561,936 Common Shares Indirect See footnotes
Series B Preferred SharesF4F4F4F2F3 2026-11-16 C - Conversion 1,611,008 D $0.00 1,611,008 Common Shares Indirect See footnotes
Warrants (right to buy)F5F7F2F3 $0.02 2026-11-16 M - Exercise 216,668 D $0.00 2036-05-12 216,668 Common Shares Indirect See footnotes
Footnotes (7)
F1
Reflects Common Shares of the Issuer purchased in the Issuer's initial public offering. Show more
F2
These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX. Show more
F3
This report on Form 4 is jointly filed by OrbiMed Advisors and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. Show more
F4
Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date. Show more
F5
The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors. Show more
F6
Reflects Common Shares withheld in connection with the Reporting Person's exercise of warrants. Show more
F7
The warrants are fully vested and exercisable. Show more
Other insiders at Windward BIO Group Ag
All Windward BIO Group Ag insider activity
GET /v1/forms/4/0000947871-26-001038 API docs
View Original SEC Filing